Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
Mallinckrodt
McKinsey
Cantor Fitzgerald
Baxter
Cipla
Harvard Business School
Cerilliant
Express Scripts

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021758

« Back to Dashboard
NDA 021758 describes VANOS, which is a drug marketed by Medicis and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VANOS profile page.

The generic ingredient in VANOS is fluocinonide. There are nine drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.

Summary for NDA: 021758

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details

Pharmacology for NDA: 021758

Suppliers and Packaging for NDA: 021758

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VANOS
fluocinonide
CREAM;TOPICAL 021758 NDA Physicians Total Care, Inc. 54868-6204 54868-6204-0 1 TUBE in 1 CARTON (54868-6204-0) > 60 g in 1 TUBE
VANOS
fluocinonide
CREAM;TOPICAL 021758 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-992 68682-992-10 1 TUBE in 1 CARTON (68682-992-10) > 120 g in 1 TUBE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.1%
Approval Date:Feb 11, 2005TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Dec 21, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jan 7, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
Patent:► SubscribePatent Expiration:Sep 11, 2022Product Flag?Substance Flag?Delist Request?
Patented Use:RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Fuji
Citi
Baxter
Mallinckrodt
Cerilliant
Boehringer Ingelheim
Johnson and Johnson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot